✦ LIBER ✦

Gemtuzumab Ozogamicin, A Potent and Selective Anti-CD33 Antibody−Calicheamicin Conjugate for Treatment of Acute Myeloid Leukemia

✍ Scribed by Hamann, Philip R.; Hinman, Lois M.; Hollander, Irwin; Beyer, Carl F.; Lindh, Delores; Holcomb, Ryan; Hallett, William; Tsou, Hwei-Ru; Upeslacis, Janis; Shochat, Dan; Mountain, Andrew; Flowers, David A.; Bernstein, Irwin

Book ID: 120558007
Publisher: American Chemical Society
Year: 2002
Tongue: English
Weight: 147 KB
Volume: 13
Category: Article
ISSN: 1043-1802
DOI: 10.1021/bc010021y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

An Anti-CD33 Antibody−Calicheamicin Conj

An Anti-CD33 Antibody−Calicheamicin Conjugate for Treatment of Acute Myeloid Leukemia. Choice of Linker

✍ Hamann, Philip R.; Hinman, Lois M.; Beyer, Carl F.; Lindh, Delores; Upeslacis, J 📂 Article 📅 2002 🏛 American Chemical Society 🌐 English ⚖ 87 KB

Molecular remission of Philadelphia/bcr-

Molecular remission of Philadelphia/bcr-abl-positive acute myeloid leukaemia after treatment with anti-CD33 calicheamicin conjugate (gemtuzumab ozogamicin, CMA-676)

✍ M. P. De Vetten; J. H. Jansen; B. A. Van Der Reijden; M. S. Berger; J. M. J. M. 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB

Phase I/II study of humanized anti-CD33

Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study

✍ Yukio Kobayashi; Kensei Tobinai; Akihiro Takeshita; Kensuke Naito; Osamu Asai; N 📂 Article 📅 2009 🏛 Carden Jennings Publishing 🌐 English ⚖ 231 KB

Efficacy and tolerability of gemtuzumab

Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg®) in children with relapsed/refractory myeloid leukemia

✍ Benoit Brethon; Anne Auvrignon; Claire Galambrun; Karima Yakouben; Thierry Lebla 📂 Article 📅 2006 🏛 BioMed Central 🌐 English ⚖ 259 KB

398 - Treatment of patients with relapse

398 - Treatment of patients with relapsed or refractory acute myelold leukemia (AML) with recombinant engineered human anti-CD33 antibody-calicheamicin drug conjugate

✍ E.L. Slevers; I.D. Bernstein; R.T. Spielberger; S.J. Forman; K. Shannon-Dorcy; F 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 223 KB

Pharmacokinetics of Gemtuzumab Ozogamici

Pharmacokinetics of Gemtuzumab Ozogamicin, an Antibody-Targeted Chemotherapy Agent for the Treatment of Patients with Acute Myeloid Leukemia in First Relapse

✍ Dowell, James A.; Korth-Bradley, Joan; Liu, Hanjiu; King, S. Peter; Berger, Mark 📂 Article 📅 2001 🏛 Sage Publications 🌐 English ⚖ 109 KB